#read

BioMed X builds a bridge between laboratory and industry

Together with Harvard University, BioMed X is launching a new pilot programme that aims to make collaboration between top academic research and the pharmaceutical industry more structured and transparent. With the so-called "XBridge Pilot", BioMed X aims to bring together scientists from Harvard laboratories with researchers from pharmaceutical companies.
13/01/2026

The focus is on clearly regulated matchmaking. BioMed X matches the research interests of its industry partners with the scientific expertise at Harvard University and develops customised project ideas. These serve as the basis for direct technical discussions between professors and industry experts. If this results in a common interest, potential research projects are formalised via the established processes of the Harvard Technology Transfer Organisation. The pilot is deliberately limited in time. Among other things, the quality of the scientific fit, the intensity of the exchange and the number of concrete research agreements are assessed. The aim is to test whether structured initiation processes are more successful than informal contacts. If the model is successful, it could lead to a long-term partnership. For biomedical research, this would be a further step towards dovetailing academic excellence and industrial development more closely without relinquishing scientific independence.

Press release of "BioMed X AG" dated 13 January 2026

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content